In the case of MYBL2, this may be due to EGFR signaling, which is frequently amplified and overexpressed in IDH-wildtype glioblastomas [56] and was reported to activate the MYBL2 promoter in association with E2F1 [57]. The gene discussed is EGFR; the disease is glioblastoma.